Big Pharma DealsHere is a brief list of comparables within the industry, with their own cancer compounds, arranged by date:
June 2010 - Bayer pays OncoMed Pharmaceuticals $540 million plus royalties for the rights to discover, develop, and commercialize novel anti-cancer stem cell teherapeutics targeting the Wnt signal pathway
August 2010 - GlaxoSmithKline pays Amplimmune $508 million plus royalties for the exclusive worldwide rights to develop and commercialize drug candidates arising from its PD-1 program for treatment of cancer.
August 2010 - Genentech pays Seattle Genetics $912 million plus royalties for the rights to develop and comercialize cancer drug candidates using Seattle Genetics' antibody-drug conjugate program.
Dec 2010 - Sanofi pays Avila Therapeutics $964 million plus royalties for the exclusive rights to develop and commercialize targeted covalent drugs for cancer treatment based on Avila's Avilomics Technology.
Oct 2010/Dec 2011 - Novartis pays ImmunoGen Inc. $466 million plus royalties for the exclusive rights to discover, develop, manufacture, and market TAP compounds for the treatment of cancer.
July 2011 - Amgen pays Micromet $1 billion plus royalties for the worldwide rights to develop and commercialize Bi-specific T cell engager antibodies against 2 solid tumor targets.
Jan 2012 - Janssen pays Forma Theapeutics $700 million plus royalties to collaborate and develop and discover drugs that target tumor metabolism mechanisms.
Jan 2012 - Boehringer Ingelheim pays Forma Therapeutics $815 million plus royalties to collaborate and discover and develop small molecule drugs against oncology- relevant protein-protein interactions.
Those deals range anywhere from $466 million to $1 billion PLUS royalties!
Theralase is targeting the $3.9 billion annually, bladder cancer market, which doctors from the Princess Margaret Hospital are confident Theralase can capture atleast 25%.
So any deal would presumably fall in line with these examples.